Pollen dimorphism and dioecy in Vitis aestivalis

Problems of low production and sterile pollen in varieties of Vitis vinifera may be tracable to their ancestral relations with dioecious wild grapes.Like V. riparia, the wild summer grape V. aestivalis has dimorphic male and female flowers; but unlike V. riparia it also has dimorphic pollen grains with the pollen from the female flower being significantly smaller.It seems fairly certain that V. aestivalis is truly dioecious

Morphological and anatomical development in the Vitaceae. VIII. Comparative development of three Cyphostemma (Vitaceae) species reveals important vegetative and reproductive differences among the species

Vegetative and floral development of Cyphostemma simulans (C.A. Small) Wild & Drummond, Cyphostemma juttae (Dinter & Gilg) Descoings, and Cyphostemma mappia (Lam) Galet were compared using epi-illumination light microscopy and paraffin sectioning. Cyphostemma simulans is a liana with leaf-opposed tendrils and inflorescences, which both arise from the shoot apical meristem, whereas the other two species are shrubs that lack tendrils and their main shoot terminates in an inflorescence. A shoot apical meristem of C. simulans can be overtopped by an inflorescence, making the architecture appear to develop like a sympodium, which is the architecture shared by the other two species. On the other hand, a terminal inflorescence of C. juttae or C. mappia can be placed in a leaf-opposed position by a precocious axillary branch, making the architecture appear to develop like a monopodium, which is the typical architecture of the Vitaceae. The floral development of all three species is similar in early ontogeny, except for a difference in calyx development between C. mappia and the other two species. Later developmental differences of the septum and gynoecium, in addition to flower colour and phenology, are distinct characteristics that distinguish flowers of each species. Therefore, this study is the first to demonstrate differences in the floral characteristics of Cyphostemma. In addition, it shows how each architecture type (monopodium or sympodium) can resemble the other and so provides stronger evidence about how the unique architecture of the Vitaceae has originated

Phase II randomized trial of radiation therapy, cetuximab, and pemetrexed with or without bevacizumab in patients with locally advanced head and neck cancer.

BackgroundWe previously reported the safety of concurrent cetuximab, an antibody against epidermal growth factor receptor (EGFR), pemetrexed, and radiation therapy (RT) in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN). In this non-comparative phase II randomized trial, we evaluated this non-platinum combination with or without bevacizumab, an inhibitor of vascular endothelial growth factor (VEGF).Patients and methodsPatients with previously untreated stage III-IVB SCCHN were randomized to receive: conventionally fractionated radiation (70 Gy), concurrent cetuximab, and concurrent pemetrexed (arm A); or the identical regimen plus concurrent bevacizumab followed by bevacizumab maintenance for 24 weeks (arm B). The primary end point was 2-year progression-free survival (PFS), with each arm compared with historical control. Exploratory analyses included the relationship of established prognostic factors to PFS and quality of life (QoL).ResultsSeventy-eight patients were randomized: 66 oropharynx (42 HPV-positive, 15 HPV-negative, 9 unknown) and 12 larynx; 38 (49%) had heavy tobacco exposure. Two-year PFS was 79% [90% confidence interval (CI) 0.69-0.92; P < 0.0001] for arm A and 75% (90% CI 0.64-0.88; P < 0.0001) for arm B, both higher than historical control. No differences in PFS were observed for stage, tobacco history, HPV status, or type of center (community versus academic). A significantly increased rate of hemorrhage occurred in arm B. SCCHN-specific QoL declined acutely, with marked improvement but residual symptom burden 1 year post-treatment.ConclusionsRT with a concurrent non-platinum regimen of cetuximab and pemetrexed is feasible in academic and community settings, demonstrating expected toxicities and promising efficacy. Adding bevacizumab increased toxicity without apparent improvement in efficacy, countering the hypothesis that dual EGFR-VEGF targeting would overcome radiation resistance, and enhance clinical benefit. Further development of cetuximab, pemetrexed, and RT will require additional prospective study in defined, high-risk populations where treatment intensification is justified